Genomic Health to Announce Third Quarter 2013 Financial Results and Host Conference Call on Tuesday, November 5, 2013 PR Newswire REDWOOD CITY, Calif., Oct. 29, 2013 REDWOOD CITY, Calif., Oct. 29, 2013 /PRNewswire/ --Genomic Health, Inc.(Nasdaq: GHDX) today announced that the company will host a conference call and webcast onTuesday, November 5 at4:30 p.m. Eastern Timeto discuss its third quarter 2013 financial results. The call and webcast will follow the release of the third quarter financial results after market close. (Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO) Conference Call Details To access the live conference call on November 5 at 4:30 p.m. Eastern Time via phone, please dial (877) 303-7208 from the United States and Canada or +1(224) 357-2389 internationally. Please dial in approximately ten minutes prior to the start of the call. To access the live and subsequently archived webcast of the conference call, go to theInvestor Relationssection of the company's website at http://investor.genomichealth.com. Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. About Genomic Health Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address the overtreatment of early stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic datainto clinically-actionable results throughout the cancer patient's journey, from screening and surveillance, to diagnosis, to treatment selection and monitoring. Genomic Health's lead product, the Oncotype DX^® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease, and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease. As of June 30, 2013, more than 19,000 physicians in over 70 countries had ordered more than 375,000 Oncotype DX tests. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth. To learn more about OncotypeDX tests, visit: www.OncotypeDX.com, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes and focus of the company's product pipeline; the applicability of clinical study results to actual outcomes; the potential economic benefits associated with the company's tests; the ability of the company to develop additional tests in the future; the demand for the company's tests; the ability of any potential tests the company may develop to optimize cancer treatment and the Company's ability to launch new tests in new markets and expand internationally. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the period ended June 30, 2013. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements. NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners. SOURCE Genomic Health, Inc. Website: http://www.genomichealth.com Contact: Investors: Dean Schorno, Genomic Health, 650-569-2281, firstname.lastname@example.org, Media: Emily Faucette, Genomic Health, 650-569-2215, email@example.com
Genomic Health to Announce Third Quarter 2013 Financial Results and Host Conference Call on Tuesday, November 5, 2013
Press spacebar to pause and continue. Press esc to stop.